On February 2, 2018, U.S. District Judge George H. Wu granted Genentech’s motion to dismiss a complaint brought by Amgen in the Central...
Genentech
-
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
-
Posted in:
Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents
By Seth Cockrum Comments are off
We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
Posted in:
Celltrion and Teva File Declaratory Judgment Action Against Thirty–Eight Herceptin®-related Patents
By Seth Cockrum Comments are off
On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...
Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, IPR, News, Patent Dance, Roche, Teva, trastuzumab
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Benjamin R. Holt Comments are off
The FDA has only approved eight biosimilar products to date. The second most recently approved biosimilar is Mvasi (bevacizumab-awwb),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
As previously reported, earlier this year Celltrion, Inc. (“Celltrion”) filed petitions seeking inter partes review (“IPR”) of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
As we previously reported, Celltrion filed three petitions seeking inter partes review (“IPR”) of two patents related to Genentech and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Andrew Storaska Comments are off
Samsung Bioepis (“Bioepis”) has joined a growing list of challengers to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213...
Tagged with: Boehringer Ingelheim, Celltrion, Genentech, Herceptin®, IPR, Legal, Mylan, News, Pfizer, Samsung Bioepsis, trastuzumab
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
Last week, Pfizer, Inc. (“Pfizer”) filed two petitions for inter partes review (“IPR”) of two patents related to Genentech and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
-
By Seth Cockrum Comments are off
On October 3, 2017, Pfizer, Inc. (“Pfizer”) filed a petition for inter partes review (“IPR”) against U.S. Patent No. 7,846,441...
Tagged with: Genentech, Herceptin®, IPR, News, Pfizer, trastuzumab
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus